Clinical Status and Design

Led by Inova Health Care Services and supported by Pfizer (PFE), NCT06023199 is a Phase 2 trial evaluating the functional effects of Oxbryta (voxelotor) in adult patients with sickle cell disease. This single-center, single-arm, open-label study began in October 2023, with six participants enrolled and the current status listed as 'Active, not recruiting.' The primary completion date is set for September 17, 2025, and the registry-scheduled study completion date is June 15, 2026. However, since the results module remains unpublished, it is more accurate to interpret the status as ongoing follow-up rather than 'clinical completion.'

Evaluation Endpoints and Clinical Significance

Participants receive Oxbryta 1,500mg once daily orally, with the primary endpoint measuring the change in 6-minute walk test (6MWT) distance over approximately six months. The Sheehan Disability Scale is also used to explore changes in work, social, and home life functions, aiming to assess whether hemoglobin increases translate into actual physical capacity and quality of life improvements. However, the lack of a control group and the small sample size of six participants make it difficult to distinguish natural progression, concurrent therapies, and learning effects, suggesting this study is more hypothesis-generating than suitable for regulatory approval.

Drug Mechanism and Regulatory Transition

Voxelotor, the active ingredient in Oxbryta, reversibly binds to sickle hemoglobin (HbS), increasing oxygen affinity and inhibiting HbS polymerization, red blood cell sickling, and hemolysis. Based on the Phase 3 HOPE trial results showing a 51.1% hemoglobin response rate compared to 6.5% with placebo over 24 weeks, the FDA granted accelerated approval for patients aged 12 and older on November 25, 2019, and expanded it to ages 4–11 in 2021. The EMA approved it on February 14, 2022, but subsequent safety signals later reversed the initial surrogate marker-based benefits.

Withdrawal Decision and Study Interpretation

Pfizer announced the global discontinuation of Oxbryta's supply and all active clinical trials on September 25, 2024, following post-marketing trial data showing higher rates of vaso-occlusive crises (VOC) and mortality compared to placebo, as well as increased VOC observed in two real-world registries. The FDA recommended discontinuation of prescriptions and switching to alternative therapies on September 26, and the European Union Executive Committee finalized marketing authorization suspension on October 4, 2024, following EMA review. Therefore, the key significance of this small functional evaluation lies in interpreting the functional effects of HbS polymerization inhibition and the clinical course of patients exposed before withdrawal, rather than commercial re-entry.

Market and Competitive Landscape

The global sickle cell disease treatment market is projected to grow from USD 2.8 billion in 2023 to USD 7.4 billion by 2030, but Oxbryta's withdrawal has created a gap in the oral disease-modifying therapy segment. Current standard-of-care includes hydroxyurea for increasing fetal hemoglobin, Emmaus Medical's Endari (L-glutamine), and P-selectin inhibitor Adakveo (crizanlizumab), along with blood transfusions and hematopoietic stem cell transplantation. In the severe patient population, Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP)'s Casgevy (exagamglogene autotemcel) and bluebird bio's Lyfgenia (lovotibeglogene autotemcel), approved by the FDA on December 8, 2023, have established themselves as curative-oriented competitive therapies.